Dr. Catherine McCuaig
Dr. Catherine McCuaig practices in Montréal, Quebec as a medical and cosmetic dermatologist. Dr. McCuaig continues to be involved with dermatological research in areas such as paediatric dermatology as well as blood vessel disorders.
Dr. McCuaig graduated from Queen’s University in 1982. She completed a degree in Internal Medicine from the University of Toronto (1982-1984) and a specialty in Dermatology from McGill University (1984-1987). A fellowship in pediatric dermatology and laser at the University of Michigan (1987-1988) was added to her academic curriculum.
Dr. McCuaig is involved in management: she is director of the fellowship program and past president of the Montreal Dermatology Society. The Lise Bachand Fellowship, awarded for research at the Université de Montréal, was awarded to Dr. McCuaig in 2014.
Thursday NOV 11
Optimal use of Topical Treatment in AD – Tips for Clinical Practice Using Crisaborole
This open session aims to:
- Review best clinical practices in topically treating AD patients
- Explore optimal use of crisaborole in mild to moderate AD
- Provide expert guidance for the real-world use of crisaborole ointment to improve patients’ outcomes
Atopic dermatitis (AD) is a lifelong inflammatory skin condition associated with altered immune function and epidermal barrier dysfunction. Mild to moderate disease is usually controlled by behavioral measures such as skin care and avoidance of triggers and treatments such as topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and crisaborole, a phosphodiesterase-4 inhibitor (PDE4-I).
Evidence from the literature coupled with the panels' expert opinion, experiences and, key insights have given rise to the recommendations on optimal crisaborole ointment use for patients with mild-to-moderate AD. The ointment provides a good and safe alternative to TCS and TCI.
The presentation discusses best clinical practices in the topical treatment of mild to moderate AD patients and provides expert guidance for the real-world use of crisaborole ointment.
Atopic dermatitis is a chronic condition in which patients may oscillate between degrees of severity over time and may have different levels of severity in various skin areas at any one time. Therefore, the best treatment paradigms reflect a need for a range of products that target these different levels of severity.
Crisaborole is a nonsteroidal PDE4-I with demonstrated efficacy in patients aged three months and older with mild to moderate AD. It is a well-tolerated alternative to TCS or TCI and can be used on any body site. It may be especially beneficial for areas with thicker skin, such as hands and feet. There are no concerning safety signals associated with crisaborole; other than its possible burning sensation. Information and education on measures to avoid side effect can help optimize results and adherence.
Cases will be presented to illustrate best clinical practices in the topical treatment of mild to moderate AD patients with crisaborole.